Next-generation small molecule therapies for heart failure: 2015 and beyond

Justin T Malinowski; David J St Jean Jr

doi:10.1016/j.bmcl.2018.03.064

Next-generation small molecule therapies for heart failure: 2015 and beyond

Bioorg Med Chem Lett. 2018 May 15;28(9):1429-1435. doi: 10.1016/j.bmcl.2018.03.064. Epub 2018 Mar 24.

Authors

Justin T Malinowski¹, David J St Jean Jr²

Affiliations

¹ Amgen Discovery Research, 360 Binney St., Cambridge, MA 02142, USA.
² Amgen Discovery Research, 360 Binney St., Cambridge, MA 02142, USA. Electronic address: david01@amgen.com.

PMID: 29615340
DOI: 10.1016/j.bmcl.2018.03.064

Abstract

Poor prognosis coupled with significant economic burden makes heart failure (HF) one of the largest issues currently facing the world population. Although a significant number of new therapies have emerged over the past 20 years to treat the underlying physiological risk factors, only two new medications specifically for HF have been approved since 2007. This perspective provides an overview of recently approved treatment options for HF and as well as an update on additional small molecule therapies currently in clinical development.

Keywords: Clinical development; Heart failure; Next generation; Small molecule.

Publication types

Review

MeSH terms

Heart Failure / diagnosis
Heart Failure / drug therapy*
Humans
Molecular Structure
Small Molecule Libraries / chemical synthesis
Small Molecule Libraries / chemistry
Small Molecule Libraries / therapeutic use*

Substances

Small Molecule Libraries